A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes children, especially those with preexisting conditions and who are older.

Palivizumab was the only approved therapy to prevent severe RSV disease in infants and young children until the approval of nirsevimab in 2023.